ResearcherUniversity of North Carolina at Chapel HillActive in the last 2 years
Hanna Kelly Sanoff
Matched on ORCID iD 0000-0001-8679-4486; OpenAlex author ID A5085949674. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 38
2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper
Papers 4
- Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreat… Co-author DOI 10.1200/po-25-00332↗
- Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal A… Co-author DOI 10.1001/jamanetworkopen.2022.49720↗
- Antibacterial Use Is Associated with an Increased Risk of Hematologic and Gastrointestinal Adverse Events in Patients Treated with Gemcitabine for Stage IV Pan… Co-author DOI 10.1634/theoncologist.2019-0570↗
- Accelerated fraction radiotherapy with capecitabine as neoadjuvant therapy for borderline resectable pancreatic cancer. Last author PMID 24558510↗
Closest collaborators
The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Brian Matthew Wolpin · 2 shared papers, 2023–2025 · strength 0.30
- Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
- Paper Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Pa… DOI 10.1001/jamanetworkopen.2022.49720↗
- Brandon M. Huffman · 2 shared papers, 2023–2025 · strength 0.30
- Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
- Paper Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Pa… DOI 10.1001/jamanetworkopen.2022.49720↗
- James M. Cleary · 2 shared papers, 2023–2025 · strength 0.30
- Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
- Paper Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Pa… DOI 10.1001/jamanetworkopen.2022.49720↗
- Harshabad Singh · 1 shared paper, 2025 · strength 0.15
- Mary Linton B. Peters · 1 shared paper, 2025 · strength 0.15
- Andrea J. Bullock · 1 shared paper, 2025 · strength 0.15
- Leah H. Biller · 1 shared paper, 2025 · strength 0.15
- ANDREA C Enzinger · 1 shared paper, 2025 · strength 0.15
- Robert James Mayer · 1 shared paper, 2025 · strength 0.15
- Douglas Adam Rubinson · 1 shared paper, 2025 · strength 0.15
- Srivatsan Raghavan · 1 shared paper, 2025 · strength 0.15
- Rishi Surana · 1 shared paper, 2025 · strength 0.15
- Hannah L. Williams · 1 shared paper, 2025 · strength 0.15
- Kimmie Ng · 1 shared paper, 2025 · strength 0.15
- Thomas Adam Abrams · 1 shared paper, 2025 · strength 0.15
- Kirsten L. Bryant · 1 shared paper, 2025 · strength 0.15
- Andrew J. Aguirre · 1 shared paper, 2025 · strength 0.15
- Matthew B.B. Yurgelun · 1 shared paper, 2025 · strength 0.15
- Aparna R. Parikh · 1 shared paper, 2025 · strength 0.15
- Channing J. Der · 1 shared paper, 2025 · strength 0.15
- Joseph Douglas Mancias · 1 shared paper, 2025 · strength 0.15
- Jonathan Andrew Nowak · 1 shared paper, 2025 · strength 0.15
- Kimberly J. Perez · 1 shared paper, 2025 · strength 0.15
- Bruno Bockorny · 1 shared paper, 2025 · strength 0.15
- Colin D. Weekes · 1 shared paper, 2025 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.